Rivaroxaban API for The Manufacture of Antithrombotic Arugs

• Customization: Available
• Function: Hormones and Regulation of Endocrine Function of Drug, Antineoplastic, Antibiotic and Antimicrobial Agents, Antiparasitic, Original Drug Resistant Microbes, Immune System Drugs, Specialist Drugs, Regulating Water and Salt, Electrolyte and Acid-Base Balance of Medicine, Drug Detoxification, Diagnostic Agents, Blood System Agents, Enzymes and Other Biochemical, Central Nervous System Agents, Cardiovascular Agents, Antidote, Respiratory System Agents, Disinfectant and Preservatives
• Certification: GMP, Reach, FDA
• Model NO.: 10kg/piece
• Type: Chemical Reagent
• State: Solid
• Volatile: Not Volatile
• Transport Package: According to Customer Requirements
• Specification: 10kg/drum
• Trademark: none
• Origin: China

Product Description

Rivaroxaban was jointly developed by Bayer Pharma in Germany and Johnson & Johnson in the United States. In October 2008, it was approved for marketing in Canada and the European Union under the trade name Xarelto. Rivaroxaban is the world's first oral direct factor Xa inhibitor that can highly selectively and competitively inhibit free and bound factor Xa and prothrombin activity, prolonging the activated partial thromboplastin time plate in a dose-dependent manner (PT) and prothrombin time (aPTT), thereby prolonging clotting time and reducing thrombin formation. It has the characteristics of high bioavailability, wide therapeutic disease spectrum, stable dose-effect relationship, convenient oral administration and low bleeding risk. Rivaroxaban is also a drug for the prevention and treatment of venous thrombosis. Clinically, it is mainly used to prevent the formation of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients after hip and knee replacement. It can also be used to prevent stroke and non-central nervous system embolism in Chemicalbook patients with non-valvular atrial fibrillation, and reduce the risk of coronary syndrome recurrence. Dabigatran is a new type of anticoagulant drug developed by Boehringer Ingelheim, Germany. In April 2008, it was first listed in Germany and the UK under the trade name Pradaxa. This is the first new oral anticoagulant drug to be marketed after warfarin in 50 years, and it is another milestone in the field of anticoagulation therapy and the prevention of potentially fatal thrombosis. Dabigatran etexilate is a novel synthetic direct thrombin inhibitor, a prodrug for oral administration, and a non-peptide thrombin inhibitor. After oral and gastrointestinal absorption, it is converted into dabigatran etexilate with direct anticoagulant activity in vivo. The drug binds to the fibrin-specific binding site of thrombin, preventing the cleavage of fibrinogen into fibrin, thereby blocking the final step of the coagulation cascade network and thrombus formation.